Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 6/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.37 |
| ▸ | WNT1 | P04628 | 4/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236557 | 0.88 | CYP3A4 (0.42) | CYP3A4CYP2D6GPR119PIK3CA | |
| SCHEMBL6110312 | 0.84 | CYP3A4 (0.38) | CYP3A4CYP2D6GSK3BDYRK1AWNT1 | |
| SCHEMBL5237058 | 0.83 | CYP3A4 (0.40) | CYP3A4CYP2D6GSK3BDYRK1AWNT1 | |
| SCHEMBL7005908 | 0.83 | CYP3A4 (0.43) | CYP3A4CYP2D6GSK3BDYRK1AWNT1 | |
| SCHEMBL5234024 | 0.82 | ALDH1A1 (0.35) | GSK3BAVPR1B | |
| Hydrochloric Acid SCHEMBL5235219 | 0.82 | CYP3A4 (0.43) | CYP3A4CYP2D6GSK3BDYRK1AWNT1 | |
| SCHEMBL5234701 | 0.81 | MAPK8 (0.44) | GSK3BAVPR1B | |
| SCHEMBL5238621 | 0.81 | PGR (0.39) | AVPR1BPTGER4 | |
| SCHEMBL6110309 | 0.80 | CYP3A4 (0.37) | CYP3A4CYP2D6GSK3BDYRK1AWNT1 | |
| SCHEMBL5234035 | 0.80 | AVPR1B (0.33) | GSK3BAVPR1BPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
| WO-2002062764-A9 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | CYP3A4 663/4885CYP2D6 992/4885GSK3B 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.